Antivascular endothelial growth factor agents pretreatment before vitrectomy for complicated proliferative diabetic retinopathy: a meta-analysis of randomised controlled trials
Open Access
- 15 December 2017
- journal article
- research article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 102 (8), 1077-1085
- https://doi.org/10.1136/bjophthalmol-2017-311344
Abstract
Background/aimsTo evaluate the efficacy of antivascular endothelial growth factor (anti-VEGF) agents pretreatment before vitrectomy for patients with complicated proliferative diabetic retinopathy (PDR).MethodsThe PubMed, Embase and the Cochrane Central Register of Controlled Trials were searched up to June 2017 to identify related studies. The Peferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines were followed. The StataSE V.12.0 software was used to analyse the relevant data. The weighted mean difference, relative risk and their 95% CIs were used to assess the strength of the association.Results14 randomised controlled trials involving 613 patients were assessed, the anti-VEGF pretreatment group included 289 patients and the control group included 324 patients. Our analysis indicated that anti-VEGF pretreatment before vitrectomy for complicated PDR could facilitate much easier surgery regarding less intraoperative bleeding, less endodiathermy, shorter duration of surgery, less iatrogenic retinal breaks, less frequency of using silicone oil and relaxing retinotomy (P0.05).ConclusionThe pretreatment of anti-VEGF agents before vitrectomy for patients with complicated PDR might facilitate much easier surgery and better visual rehabilitation, reduce the rate of early recurrent VH and accelerate its absorption. Moreover, future better-designed studies with larger sample sizes are required to further evaluate the efficacy of different anti-VEGF agents and reach a firmer conclusion.Keywords
This publication has 39 references indexed in Scilit:
- A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathyBritish Journal of Ophthalmology, 2012
- PREOPERATIVE INJECTION OF INTRAVITREAL BEVACIZUMAB IN DENSE DIABETIC VITREOUS HEMORRHAGERetina, 2011
- A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathyBritish Journal of Ophthalmology, 2011
- Intravitreal Bevacizumab for Prevention of Early Postvitrectomy Hemorrhage in Diabetic PatientsA Randomized Clinical TrialOphthalmology, 2009
- 2009 Updated Method Guidelines for Systematic Reviews in the Cochrane Back Review GroupSpine, 2009
- Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study)British Journal of Ophthalmology, 2009
- Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathyBritish Journal of Ophthalmology, 2007
- Overview of Epidemiologic Studies of Diabetic RetinopathyOphthalmic Epidemiology, 2007
- VITREOUS LEVELS OF UNBOUND BEVACIZUMAB AND UNBOUND VASCULAR ENDOTHELIAL GROWTH FACTOR IN TWO PATIENTSRetina, 2006
- Effect of tranexamic acid on early postvitrectomy diabetic haemorrhage; a randomised clinical trialBritish Journal of Ophthalmology, 2005